American Cancer Society Guideline for the Early Detection of Prostate Cancer: Update 2010

  title={American Cancer Society Guideline for the Early Detection of Prostate Cancer: Update 2010},
  author={Andrew M.D. Wolf and Richard C Wender and Ruth Etzioni and Ian M. Thompson and Anthony V. D'Amico and Robert J. Volk and Durado D Brooks and Chiranjeev Dash and Idris Guessous and Kimberly S. Andrews and Carol E DeSantis and Robert A. Smith},
  journal={CA: A Cancer Journal for Clinicians},
In 2009, the American Cancer Society (ACS) Prostate Cancer Advisory Committee began the process of a complete update of recommendations for early prostate cancer detection. [] Key Method The results of the systematic reviews were evaluated by the ACS Prostate Cancer Advisory Committee, and deliberations about the evidence occurred at committee meetings and during conference calls.

Cancer Screening in the United States, 2010: A Review of Current American Cancer Society Guidelines and Issues in Cancer Screening

The current ACS guidelines and recent issues are summarized, updates of guidelines for testing for early breast cancer detection by the US Preventive Services Task Force and for prevention and early detection of cervical cancer from the American College of Obstetricians and Gynecologists are addressed, and the most recent data from the National Health Interview Survey pertaining to participation rates in cancer screening are described.

Screening for Prostate Cancer: A Guidance Statement From the Clinical Guidelines Committee of the American College of Physicians

The American College of Physicians developed this guidance statement for clinicians by assessing current prostate cancer screening guidelines developed by other organizations to critically review available guidelines to help guide internists and other clinicians in making decisions about screening for prostate cancer.

Prostate cancer screening: guidelines review and laboratory issues

The quality of PCa early detection guidelines could be improved properly considering the laboratory issues in their development, according to a systematic review of guidelines about PCa screening using PSA.

Screening for prostate cancer with the prostate-specific antigen test: a review of current evidence.

IMPORTANCE Prostate cancer screening with the prostate-specific antigen (PSA) test remains controversial. OBJECTIVE To review evidence from randomized trials and related modeling studies examining

Prostate Cancer: A Primary Care Perspective

The indications for repeat prostate biopsy in a man with an elevated PSA and a negative initial biopsy are not well studied, and the presence of atypia or low levels of free PSA may indicate a higher risk of prostate cancer in these individuals.

What we have learned from randomized trials of prostate cancer screening.

Prostate cancer screening efforts would benefit from improved biomarkers, which more readily identify clinically important cancers, and cancer control efforts might also need to include chemoprevention, though currently available agents are controversial.

The Ethical Dilemma Surrounding Prostate Specific Antigen (PSA) Screening

Ethical considerations of PSA screening for prostate cancer are examined and it is important to understand implications of the debate for clinicians and men.

Prostate‐specific antigen screening: A critical review of current research and guidelines

A critical review of the current guidelines and research is served to determine which screening practices may be most beneficial to utilize with patients to support guideline recommendations against routine screening of asymptomatic men.



Screening men for prostate and colorectal cancer in the United States: does practice reflect the evidence?

Among men in the United States, prostate cancer screening is more common than colorectal cancer screening, and Physicians should ensure that men who choose to be screened for cancer are aware of the known mortality benefit of colore CT screening and the uncertain benefits of screening for prostate cancer.

Mortality results from a randomized prostate-cancer screening trial.

After 7 to 10 years of follow-up, the rate of death from prostate cancer was very low and did not differ significantly between the two study groups.

Trials of decision aids for prostate cancer screening: a systematic review.

Cancer surveillance series: interpreting trends in prostate cancer--part I: Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates.

The decline in the incidence of distant stage disease holds the promise that testing for prostate-specific antigen may lead to a sustained decline in prostate cancer mortality, however, population data are complex, and it is difficult to confidently attribute relatively small changes in mortality to any one cause.

American Cancer Society guideline for the early detection of prostate cancer: Update 1997

This guideline for the early detection of prostate cancer is based on knowledge gained by a critical analysis of experience since the original version of 1992 and is offered to health care professionals seeking to provide optimal care to asymptomatic men at risk for prostate cancer.

Detection of prostate cancer: the impact of the European Randomized Study of Screening for Prostate Cancer (ERSPC).

Important aspects relating to recent findings from the ERSPC about first, leadtime and overdiagnosis, and second, prostate-specific antigen (PSA) as a test for repeated screening are focused on.

Screening and prostate-cancer mortality in a randomized European study.

PSA-based screening reduced the rate of death from prostate cancer by 20% but was associated with a high risk of overdiagnosis.